ARCHIVES

Analysis Reveals Patient Subset With Lower PFS in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 34 No. 12 | December 30, 2011

Download PDF Visit The Full Archive

Related Articles

BioSeek Awarded NIH SBIR For Compound Validation.

July 4, 2003

R.S.K. Young Quits As FDA Oncology Group Leader

July 11, 1980

Rituximab Prolonged Survival Of CLL In Phase III Study

September 24, 2010

NCI To Offer Expanded Access To Oxaliplatin

May 31, 2002

NCI reassigns project officer John Gohagan.

April 16, 2004

Study: Robotic-Assisted Surgery Offers Better Cancer Control

March 28, 2014